BIOLASE, Inc.

Federico Pignatelli, Chairman & CEO

Alexander K. Arrow, MD, President & COO

NASDAQ: BIOL

www.biolase.com

Investor Update

September 2013

Exhibit 99.1

Safe Harbor Statement

This

presentation

may

contain

forward-looking

statements

that

are

based

on

our

current

expectations,

estimates

and

projections

about

our

industry

as

well

as

management’s

beliefs

and

assumptions.

Words

such

as

“anticipates,”

“expects,”

“intends,”

“plans,”

“believes,”

“seeks,”

“estimates,”

“may,”

“will,”

and

variations

of

these

words

or

similar

expressions

are

intended

to

identify

forward-looking

statements.

These

statements

include

projections

about

our

future

earnings

and

margins

and

speak

only

as

of

the

date

hereof.

Such

statements

are

based

upon

the

information

available

to

us

now

and

are

subject

to

change.

We

will

not

necessarily

inform

you

of

such

changes.

These

statements

are

not

guarantees

of

future

performance

and

are

subject

to

certain

risks,

uncertainties

and

assumptions

that

are

difficult

to

predict.

Therefore

our

actual

results

could

differ

materially

and

adversely

from

those

expressed

in

any

forward-looking

statements

as

a

result

of

various

factors.

The

important

factors

which

could

cause

actual

results

to

differ

materially

from

those

in

the

forward-looking

statements

include,

among

others,

a

downturn

or

leveling

off

of

demand

for

our

products

due

to

the

availability

and

pricing

of

competing

products

and

technologies,

adverse

international

market

or

political

conditions,

a

domestic

economic

recession,

the

volume

and

pricing

of

product

sales,

our

ability

to

control

costs,

intellectual

property

disputes,

the

effects

of

natural

disasters

and

other

events

beyond

our

control

and

other

factors

including

those

detailed

in

BIOLASE’s

filings

with

the

Securities

and

Exchange

Commission

including

its

prior

filings

on

Form

10-K

and

10-Q.

PAGE

2

BIOLASE has:

•

Invented,

•

Developed,

•

Patented,

and been granted FDA clearances for

a fundamentally different kind of tissue-cutting tool

PAGE

3

•

Water molecules within tissue absorb laser

energy from the WaterLase and vaporize,

resulting in an atraumatic ablation of the

tissue.

–

Very little trauma or bleeding,

–

No heat or vibration, and

–

Little or no pain

–

Significantly reduces cross contamination

WaterLase All-Tissue Lasers

PAGE

4

•

Extensive patent protection

•

Multiple other medical applications

Patient Testimony

PAGE 5

How It Works: WaterLase High Speed Cutting

PAGE 6

WaterLase Atraumatic Pediatric Tooth Extraction

The aiming beam 

does not cut the

tissue nor

generate heat. 

The tissue is cut

biologically, with

little or no pain,

when the laser

energizes water

at the molecular

level.

PAGE 7

PAGE

8

Digital

Imaging:

Best-in-class

digital

imaging

equipment,

including cone beam  3-D dental imaging and CAD/CAM

digital dental impressions.

Non-Dental:

The

EPIC-V,

and

coming

soon,

the

EPIC-S

Diode soft-tissue dental lasers: The EPIC 10 Soft Tissue

laser, which in June 2013 won the MDE gold medal in

medical device design, and the iLase, a portable diode

laser with no foot pedal, power cord, or external controls.

BIOLASE Products

PAGE 9

All-tissue

dental

lasers:

Our

flagship

laser,

the

WaterLase

iPlus, and the WaterLase MD Turbo.

Our

near

term

focus

is

to

continue

to

emphasize

our

core

dental

laser

business

and

our

growing

line

of

digital

imaging

systems

and

CAD/CAM

intra-oral

scanners.

We

entered

the

Veterinary

market

in

Q3

2013

and

may

enter

the

ENT

market

in

Q4

2013.

Diversification in 2013

PAGE 10

2012 (Actual)

2013 (Projected)

Dental Laser Systems

~74%

68-70%

Imaging Systems

~6%

8-10%

Consumables

~10%

10-12%

Services

~10%

10-12%

License fees and Royalty

Less than 1%

1-2%

ENT Laser Systems

-

TBD

Veterinary Laser Systems

-

New Launch

Why Should Dentists Buy a Waterlase iPlus?

•

WaterLase

enables

dentists

to

perform

procedures

that

they

would

otherwise

refer

to

specialists,

for

example:

•

Gingivectomy = $160-$200

•

Perio Treatment = $375-$1,000

•

Hard-tissue Crown Lengthening = $500-$700

•

Herpetic

or

Aphthous

Ulcer

=

$300

-

$500

•

Frenectomy = $400-$600

•

These procedures are easy to learn and training is included in the cost.

•

With no anesthesia, the WaterLase also increases efficiency and allows the dentist to work in multiple

quadrants in a single visit., equating to $250-$750 per day in additional revenue.

Monthly Finance Payment

New Monthly Revenue Generated

Approx. $1,300

$5,000 –

$15,000

PAGE 11

A dentists’

return on investment can

be 500% to 1,500%

Return on Investment

•

WaterLase dentists offer their customers more

procedures

and they have a higher rate of acceptance. 

Patients are more likely to accept treatment if it does not

hurt them.

•

Case Study:  Doctor David Peck

(Springfield, MA)

–

$1M practice in 2010; purchased a WaterLase iPlus

in January 2011.

–

Practice grew to $1.7M in 2011; For example, Dr.

Peck performed 75 frenectomies in 2011 that

generated $35,000 of revenues.  That’s a total of

about 90 minutes of work.

–

Purchased second WaterLase iPlus in Sept 2012; practice

grew to $2.0M in 2012.

Value Proposition of WaterLase

PAGE 12

Who have we been selling to?

PAGE

13

•

EPIC 10 total diode solution

–

regulatory clearance late Q3 (EU) & early Q4

(US) 2012.

–

cleared for 3 unique uses:

Soft Tissue Surgery,

Whitening,

Pain Therapy.

Diode Soft-Tissue Dental Lasers

PAGE 14

•

iLase

–

portable diode laser.

–

no foot pedal, power cord, or external controls.

•

TRIOS intra-oral

scanner and cart:

–

digital

impression

taking.

–

handheld

scanner,

operator's

control cart,

and software.

–

North American

distribution

agreement

through Aug

2017.

In-Licensed Products

•

NewTom/Cefla 3D

cone beam

imaging products:

–

medical grade

imaging

technology.

–

less cost, less

radiation

exposure.

–

U.S. & Canada

distribution

agreement

through Feb 2015.

PAGE 15

Da Vinci Imaging is Ready to Help Laser Sales

Core Laser Business

Biolase Da Vinci Imaging

PAGE

16

PAGE

17

PAGE

18

BIOLASE lasers are to other cutting tools like a smart

phone is to a telephone

PAGE

19

The Dental Drill vs. the WaterLase

PAGE

20

The Scalpel vs. the Epic

PAGE

21

Annual Net Revenue and Stock Price

PAGE 22

Projected revenue guidance of

approximately $68 million, last

updated August 7, 2013.

Quarterly Net Revenue and Influencers in Turnaround

PAGE 23

•

160,000 dentists in US & Canada.

1

•

Approximately 1.5 M dentists in 134

countries.

–

rapid growth in emerging economies

2

e.g. China, India & Indonesia.

•

Current market penetration.

–

approx. 5.0% of dental practices in US.

–

approx. 1.5% worldwide.

•

Each incremental 1% market penetration equals over $600M

revenue.

•

Dental laser market opportunity is over $50B.

BIOLASE’s Market Opportunity

Est. total global market

BIOLASE systems sold worldwide 1998-present

1

American Dental Association. 

2

World Federation of Dentistry. 

PAGE 24

Dominant Market Position

WW Hard-tissue Dental Laser Market

WW Total Dental Laser Market

80%

45%

BIOLASE Market Share

PAGE 25

WaterLase Technology Substantially Reduces

the Risk of Cross Contamination and Contagion

Burs and Endo

Files:

WaterLase

Tips:

•Complex and rugged bur surface difficult to sterilize.

•Smooth tip surface does not harbor debris or

bacteria like abrasive surface of burs or files.

•YSGG laser energy is bacteriacidal.³

•Disposable tips work without the need to contact tissue. 

Also eliminates accidental sticks with contaminated burs.

•15% of “sterilized”

burs and up to 76% of “sterilized”

endodontic files carry pathogenic micro-organisms.

1, 2

•Autoclaving fails one out of every seven times to

decontaminate burs.¹

1.

Dental

Burs

and

Endodontic

Files:

Are

Routine

Sterilization

Procedures

Effective?:

Archie

Morrison,

DDS,

MS,

FRCD(C);

Susan

Conrod,

DDS

JCDA

•

www.cda-adc.ca/jcda

•

February

2009,

Vol.

75,

No.

1.

2.

Contaminated

dental

instruments:

Smith

A,

Dickson

M,

Aitken

J,

Bagg

J.J

Hosp

Infect.

2002

Jul;51(3):233-5.

3.

The

antimicrobial

efficacy

of

the

erbium,

chromium:yttrium-scandium-gallium-garnet

laser

with

radial

emitting

tips

on

root

canal

dentin

walls

infected

with

Enterococcus

faecalis:

Wanda

Gordon,

DMD,

Vahid

A.

Atabakhsh,

DDS,

Fernando

Meza,

DMD,

Aaron

Doms,

DDS,

Roni

Nissan,

DMD,

Ioana

Rizoiu,

MS

and

Roy

H.

Stevens,

DDS,

MS

JADA

2007;

138(7):

992-1002

PAGE

26

PAGE 27

•

314 patents issued & pending.

•

70% are related to WaterLase technology & medical lasers.

Extensive Patent Portfolio

Issued &

Active

Pending

Total

U.S.

80

44

124

International

82

108

190

Total

162

152

314

•

Continued sustained top line growth

•

Non-GAAP profitability, GAAP profitability, becoming cash

flow positive

•

Launching 1-2 major new products per year

•

Entering one new non-dental market per year

•

Alleviating working capital constraints that have been hurting

our operating margins and our progress

•

Return to our reputation as a product-driven company

Corporate Goals

PAGE

28

BIOLASE Corporate Headquarters in Irvine, California

PAGE 29

•

Sales offices in Floss (Germany), Madrid (Spain),

Shanghai (China), and Mumbai (India); expansion

planned in Dubai (UAE), and Rio de Janero (Brazil).

•

Floss also has service and manufacturing capabilities.

•

Training facility at corporate HQ with access to state-of-

the-art facilities throughout the U.S. & Internationally.

BIOLASE Europe in Floss, Germany

•

57,000 sq. ft. facility in Irvine, California, includes

manufacturing and development facilities.

•

Can accommodate growth to $250 million.

•

Over 210 employees worldwide.

BIOLASE Facilities & Employees

•

The “big story”

potential of pipeline products in at least five

new markets (orthopedics, ophthalmology, ENT surgery,

podiatry, and veterinary surgery)

•

The stability and risk-reduction of an established growing

business in its first market: dentistry

•

With BIOLASE, you get both advantages in one company: (1)

potential upside from a deep pipeline, and (2) an established

growth business –

at a very low multiple of revenues

A Growth Story with

Proof-of-Concept

PAGE

30

Management and Board of Directors

Management

–

Salary $1, ownership position 5.5%

–

Ownership position: 1.5%

–

Ownership position: 0.7%

Board of Directors

PAGE

31

•

Federico Pignatelli, Chairman

•

Gregory Lichtwardt

•

Erin Enright

•

Frederic Moll, MD

•

Alexander Arrow, MD

•

Norman Nemoy, MD

•

Federico Pignatelli, CEO

•

Alexander Arrow, President & COO

•

Frederick Furry, CFO

•

Bill Brown, VP Bus Dev & Sales

•

Orlando Rodrigues, VP Marketing

•

Dmitri Boutoussov, VP R&D

•

Colleen Boswell, VP RA/QA